Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Allogeneic Mesenchymal Bone Marrow Cells in STEMI
NCT01770613Phase 2Withdrawn
- Sponsor
- Stemedica Cell Technologies
- Start
- Feb 2013
- Primary completion
- May 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic mesenchymal bone marrow cells in ST-elevation myocardial infarction (STEMI), sponsored by Stemedica Cell Technologies. Planned start Feb 2013; status: withdrawn.
02
Drugs
allogeneic mesenchymal bone marrow cells
03
Conditions
ST-elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT01770613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01770613.